Breaking News

Financial Report: WuXi Pharma Tech 3Q

November 13, 2012

Lab Services up 26%, driven by China-based labs

WuXi Pharma Tech

3Q Revenues: $125.8 million (+21%)

3Q Earnings: $213 million (+3%)

YTD Revenues: $374.3 million (+25%)

YTD Earnings: $62.8 million (+9%)

Comments: Laboratory Services were $98.9 million in the quarter, up 26%. China-based Lab Services increased 32% to $77.0 million. U.S.-based Lab Services were up 6% to $21.9 million. Manufacturing services were $26.9 million, up 7%.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks